| Stroke |
CR2-Crry and CR2-fH |
[45, 84, 85] |
| Traumatic brain injury |
CR2-Crry, CR2-fH and CR2-CD59 |
[57, 59] |
| Spinal cord injury |
CR2-Crry |
[86] |
| Experimental autoimmune encephalomyelitis (MS) |
CR2-Crry and CR2-fH |
[87] |
| Post-transplant cardiac IRI |
CR2-Crry and CR2-fH |
[63] |
| Vascularized composite allograft transplantation with and without immunosuppression |
CR2-Crry |
[64] |
| Donor brain death and cardiac IRI |
CR2-Crry |
[66] |
| Liver transplantation (lean and steatotic grafts), hepatic IRI and liver regeneration |
CR2-Crry and CR2-CD59 |
[22, 25, 88] |
| LPS/D-GalN-induced fulminant hepatic failure |
CR2-fH |
[89] |
| Graft ischemia in rejection of orthotopic tracheal transplants |
CR2-Crry |
[65] |
| Kidney transplantation and delayed graft function |
TT30 (humanized CR2-fH) |
[90] |
| Intestine IRI and secondary lung injury |
CR2-Crry and CR2-fH |
[26, 53] |
| C3 glomerulopathy |
CR2-fH |
[34] |
| Lupus |
CR2-Crry, CR2-fH and sCR2 |
[27, 60, 61] |
| Arthritis (CIA and CAIA) |
CR2-Crry and CR2-fH |
[91, 92] |
| Age related macular degeneration (including gene therapy approach) |
CR2-Crry, CR2-fH, CR2-CD59 and TT30 (humanized CR2-fH) |
[58, 83, 93, 94] |
| Smoke induced ocular injury |
CR2-fH |
[95] |
| Hemorrhage |
CR2-fH |
[96] |
| PNH erythrocytes |
CR2-fH |
[55, 69] |
| Preeclampsia |
CR2-Crry |
[97] |
| Atherosclerosis |
CR2-Crry |
[98] |
| DSS colitis (including oral delivery of CR2-Crry) |
CR2-Crry and CR2-fH |
[99–101] |
| Paraquat-induced lung injury |
CR2-Crry and CR2-fH |
[102] |
| PMN recruitment in response to adenovirus and effect on eliminating virus-containing cells |
CR2-Crry and CR2-fH |
[103] |
| Polymicrobial sepsis |
CR2-Crry |
[26] |
| In vitro cell targeting and activity, in vivo targeting to kidney in lupus model |
Human CR2-DAF and CR2-CD59 |
[17] |
